Skip to main content
Article thumbnail
Location of Repository

Antidiabetic Action of Bezafibrate in a Large Observational Database

By James H. Flory, Susan Ellenberg, Philippe O. Szapary, Brian L. Strom and Sean Hennessy
Topics: Original Research
Publisher: American Diabetes Association
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. AMPK and PPAR agonists are exercise mimetics.
  2. BL: Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 11:211–218,
  3. (2000). Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects. Nutr Metab Cardiovasc Dis 10:1–6,
  4. (2008). Connolly TM: Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr Opin Investig Drugs 9:247–255,
  5. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
  6. (2004). Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. Diabetes Obes Metab 4:187–194,
  7. (2002). General Practice Research Database [online],
  8. (2008). GoldfineAB:Assessingthecardiovascular safety of diabetes therapies.
  9. (2000). Henke BR: The PPARs: from orphan receptorstodrugdiscovery.JMedChem43: 527–550,
  10. (2007). Investigators: Effect of fenofibrate on the need for laser treatment for diabeticretinopathy(FIELDstudy):arandomised controlled trial. Lancet 370: 1687–1697,
  11. (2005). Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861,
  12. (2006). MotroM,BeharS:Attenuationofprogression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 166:737–741,
  13. (2009). MR: Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
  14. (2004). Peroxisome proliferator-activated receptorligandbezafibrateforpreventionof type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197–2202,
  15. (2007). Prevention of type 2 diabetes: fact or fiction? Expert Opin Pharmacother 8:3147–3158,
  16. (2000). Pta ´ckova ´ K, Dusinska ´ M: Effect of ciprofibrateonlipoproteinmetabolismandoxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
  17. (2005). S: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
  18. (2005). Selling safety—lessons from muraglitazar.
  19. (2003). SM: Effects of adding fenofibrate (200 mg/ day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
  20. Vessby B: A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulindependent diabetes mellitus and hyperlipoproteinemia.
  21. (2003). YangCC,JickSS,TestaMA:Whoreceives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation.
  22. (2001). ZimmetP,AlbertiKG,ShawJ:Globaland societal implications of the diabetes epidemic.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.